International Journal of Biological Macromolecules APC and Open Access: Current Elsevier Pricing, 12-Month Green OA, and When Gold Is Worth It

Elsevier's current open-access page for IJBM gives a much cleaner answer than the older generic pricing ranges:

• USD 4,170 APC for all article types published gold OA
• subscription route available with no gold-OA charge
• 12-month embargo for public repository release of subscription papers
• registered report discounts listed on-page:
• 20% discount at Stage 1
• 100% discount at Stage 2

That means the real route menu is:

For most authors, the real question is whether immediate final-version openness changes the paper's outcome enough to justify the fee. In many cases, the answer depends more on funding coverage and target audience than on the journal itself.

The APC is attached to a journal with real citation strength, but also to a very broad and very high-volume title. That matters because the economic case for paying gold OA is different here than at a smaller, more selective biopolymer journal.

The year-over-year move is positive. IJBM is up from 7.9 in 2023 to 8.5 in 2024. That is useful context for authors because it shows the journal is still gaining citation strength even while operating at scale.

At IJBM, the gold route is not competing with zero visibility. It is competing with a journal that already has:

• broad ScienceDirect distribution
• strong institutional-library penetration
• substantial traffic from biomaterials, food science, and macromolecule labs

That means the subscription route is often still workable for authors whose:

• funders allow an embargoed green route
• main readers already have library access
• paper is unlikely to gain much from immediate public visibility

Gold OA becomes easier to defend when:

• the corresponding author has Elsevier agreement coverage
• the paper serves a broad international applied audience outside well-funded university libraries
• the team needs immediate final-version access rather than accepted-manuscript access later

In our pre-submission review work, authors often price IJBM against other biomaterials or polymer journals by looking only at the headline APC. That is incomplete. The more useful comparison is:

• whether the journal gives you a no-APC subscription route
• whether the accepted-manuscript embargo is tolerable
• whether your actual audience needs the final version of record immediately

IJBM is stronger than many broad applied journals on that middle point because the 12-month green route is workable for many funded academic teams. If your grant or institutional policy does not force immediate gold OA, the practical choice is often to spend the money on figure support, extra validation, or language editing instead of buying immediate open distribution.

In our pre-submission review work, the most common mistake is not fee planning. It is paying attention to the APC before deciding whether the paper is actually an IJBM paper.

What usually works:

• a clear biological macromolecule at the center of the story
• functional evidence, not just characterization
• application logic that fits biomaterials, food, or biomedical use

What usually creates regret:

• treating a structure-and-characterization paper like a biological macromolecule paper
• trying to buy visibility with gold OA when the paper still has a fit problem
• assuming the broad scope means the editorial bar on biological consequence is low

That is why the green route matters here. If the paper is a good fit but budget is tight, subscription plus repository release later is often rational.

For International Journal of Biological Macromolecules APC, the current answer is cleaner than many older pages suggest:

• gold OA: USD 4,170
• subscription: no gold APC
• green OA: accepted manuscript after a 12-month embargo

That means the decision is not just "can we afford the APC?" It is "does immediate final-version openness create enough extra value over the subscription and green routes?"